Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

AZN PEER ANALYSIS

AstraZeneca PLC — metric-by-metric comparison with peers and the industry median

AZNAstraZeneca PLC

🇬🇧 UK · LSE · Healthcare · Drug Manufacturers - General

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Drug Manufacturers - General

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial HealthDividend
AZNIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
AZN+38.8%OGN+37.3%GRF-13.3%AZN+36.0%BIIB+56.9%BAYN+95.9%
Year-to-Date (YTD)
AZN+3.3%OGN+89.9%GRF-15.3%AZN+7.5%BIIB+18.4%BAYN+38.7%
1-Year
Split-adjusted
AZN+38.8%GSK+46.5%
Year-to-Date (YTD)
AZN+3.3%GSK+10.6%

Key Metric Comparison

P/E

Lower is better
AZN28.08OGN14.49GRF14.86AZN28.27BIIB22.54BAYN—Median 22.54

ROE

Higher is better
AZN23.7%OGN34.0%GRF7.5%AZN23.5%BIIB7.7%BAYN-7.0%Median 23.7%

Net Margin

Higher is better
AZN17.2%OGN4.0%GRF5.6%AZN17.2%BIIB13.9%BAYN-4.8%Median 15.0%

Revenue Growth

Higher is better
AZN9.7%OGN-2.1%GRF0.9%AZN9.9%BIIB0.4%BAYN-2.9%Median 3.3%

P/E

Lower is better
AZN28.08GSK13.86Median 22.54

ROE

Higher is better
AZN23.7%GSK36.4%Median 23.7%

Net Margin

Higher is better
AZN17.2%GSK17.8%Median 15.0%

Revenue Growth

Higher is better
AZN9.7%GSK4.0%Median 3.3%

All Metrics

Valuation
MetricAZNOGNGRFAZNBIIBBAYNInd. Median
P/E28.0814.49●14.8628.2722.54—22.54
P/B6.203.951.13●6.201.661.744.53
EV/EBITDA15.577.97●10.5315.6912.2923.5313.48
P/S4.830.58●0.834.863.141.113.14
Financial Health
MetricAZNOGNGRFAZNBIIBBAYNInd. Median
Current Ratio0.911.972.470.913.06●1.061.25
Debt/Equity71.7%948.9%177.2%71.7%35.2%●134.8%94.3%
NetDebt/EBITDA1.285.396.221.290.84●9.191.35
Profitability
MetricAZNOGNGRFAZNBIIBBAYNInd. Median
Net Margin17.2%4.0%5.6%17.2%●13.9%-4.8%15.0%
ROE23.7%34.0%●7.5%23.5%7.7%-7.0%23.7%
ROA9.5%●1.9%2.0%9.4%4.8%-2.0%8.0%
EBITDA Margin33.8%●22.4%19.3%33.7%27.4%7.7%28.4%
Growth + Dividend
MetricAZNOGNGRFAZNBIIBBAYNInd. Median
Rev. Growth9.7%-2.1%0.9%9.9%●0.4%-2.9%3.3%
NI Growth32.9%-67.2%112.7%●33.7%-7.2%—32.9%
Div. Yield2.2%●0.6%2.1%0.2%—0.2%2.1%
Payout47.0%8.9%30.8%47.3%—-5.9%45.7%
Valuation
MetricAZNGSKInd. Median
P/E28.0813.86●22.54
P/B6.204.53●4.53
EV/EBITDA15.578.34●13.48
P/S4.832.46●3.14
Financial Health
MetricAZNGSKInd. Median
Current Ratio0.91●0.791.25
Debt/Equity71.7%●106.7%94.3%
NetDebt/EBITDA1.28●1.351.35
Profitability
MetricAZNGSKInd. Median
Net Margin17.2%17.8%●15.0%
ROE23.7%36.4%●23.7%
ROA9.5%●9.4%8.0%
EBITDA Margin33.8%35.3%●28.4%
Growth + Dividend
MetricAZNGSKInd. Median
Rev. Growth9.7%●4.0%3.3%
NI Growth32.9%84.9%●32.9%
Div. Yield2.2%3.3%●2.1%
Payout47.0%44.5%45.7%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on AZN

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.